Patient management issues in metastatic bone disease

Coleman, 1997, Skeletal complications of malignancy, Cancer, 80, 1568 Maxwell, 2003, Advances in supportive care of patients with cancer and bone metastases, Clin J Oncol Nurs, 7, 403, 10.1188/03.CJON.403-408 DesHarnais Castel, 2001, A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease, Support Care Cancer, 9, 545, 10.1007/s005200100249 Hillner, 2003, American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer, J Clin Oncol, 21, 4042, 10.1200/JCO.2003.08.017 Chang, 2003, Renal failure with the use of zoledronic acid, N Engl J Med, 349, 1676, 10.1056/NEJM200310233491721 Hillner, 2000, Pamidronate in prevention of bone complications in metastatic breast cancer, J Clin Oncol, 18, 72, 10.1200/JCO.2000.18.1.72 Body, 2003, Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases, Ann Oncol, 14, 1399, 10.1093/annonc/mdg367 Bell, 2004, Renal safety of ibandronate in patients with bone metastases from breast cancer, Eur J Cancer Suppl, 2, 132, 10.1016/S1359-6349(04)90866-X Body, 2004, Safety of an intravenous (i.v.) loading dose of ibandronate followed by daily oral dosing in metastatic bone disease, Proc Am Soc Clin Oncol, 23, 60 Neugebauer, 2001, Influence of peak ibandronic acid concentrations after 6 mg i.v. administration with shortened infusion time (15 and 30 minutes) on renal safety in man, Proc Am Soc Clin Oncol, 20, 122A Liu, 1997, Patient preferences for oral versus intravenous palliative chemotherapy, J Clin Oncol, 15, 110, 10.1200/JCO.1997.15.1.110 O’Neill, 2002, Oral cancer treatment, Br J Cancer, 87, 933, 10.1038/sj.bjc.6600591 Body, 2004, Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease, Br J Cancer, 90, 1133, 10.1038/sj.bjc.6601663 Body, 2003, Effectiveness and cost of bisphosphonate therapy in tumor bone disease, Cancer, 97, 859, 10.1002/cncr.11139 Delea, 2004, Impact of skeletal complications on total medical care costs in breast cancer patients with bone metastases, Bone, 34, S86 Liberato, 2003, Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates, Drugs Aging, 20, 631, 10.2165/00002512-200320090-00001 McCloskey, 2001, The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma, Drugs, 61, 1253, 10.2165/00003495-200161090-00003 Liberato, 2000, Pamidronate in advanced breast cancer, Eur J Cancer, 36, S4 Biermann, 1991, An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone, Bone, 12, S37, 10.1016/8756-3282(91)90066-R Guignard, 1997, Economic assessment of clodronate in the preventative treatment of bone resorption in patients with metastatic breast cancer, Eur J Cancer, 33, 25, 10.1016/S0959-8049(97)85943-6 Bruce, 1999, Economic impact of using clodronate in the management of patients with multiple myeloma, Br J Haematol, 104, 358, 10.1046/j.1365-2141.1999.01194.x Dranitsaris, 1999, Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer, Support Care Cancer, 7, 271, 10.1007/s005200050260